Wells Fargo
TRDA icon

Wells Fargo’s Entrada Therapeutics TRDA Stock Holding History

Wells Fargo’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$139K Sell
11,011
-21,152
-66% -$242K ﹤0.01% 4925
2025
Q4 		$331K Buy
32,163
+10,547
+49% +$88.9K ﹤0.01% 4772
2025
Q3 		$125K Buy
21,616
+3,516
+19% +$20.6K ﹤0.01% 5197
2025
Q2 		$122K Buy
18,100
+3,230
+22% +$26K ﹤0.01% 5080
2025
Q1 		$134K Buy
14,870
+127
+0.9% +$1.58K ﹤0.01% 4933
2024
Q4 		$255K Buy
14,743
+3,357
+29% +$60.8K ﹤0.01% 4647
2024
Q3 		$182K Buy
11,386
+487
+4% +$7.67K ﹤0.01% 4644
2024
Q2 		$155K Buy
10,899
+3,302
+43% +$46.9K ﹤0.01% 4675
2024
Q1 		$108K Buy
7,597
+970
+15% +$13.7K ﹤0.01% 4850
2023
Q4 		$100K Buy
6,627
+1,300
+24% +$19.3K ﹤0.01% 4897
2023
Q3 		$84.2K Sell
5,327
-2,853
-35% -$44.9K ﹤0.01% 4881
2023
Q2 		$124K Buy
8,180
+8,011
+4,740% +$110K ﹤0.01% 4905
2023
Q1 		$2.45K Buy
169
+1
+0.6% +$13 ﹤0.01% 6194
2022
Q4 		$2.27K Buy
168
+3
+2% +$53 ﹤0.01% 5982
2022
Q3 		$3K Buy
165
+52
+46% +$660 ﹤0.01% 6086
2022
Q2 		$2K Sell
113
-2,172
-95% -$16.5K ﹤0.01% 6382
2022
Q1 		$21K Sell
2,285
-3,035
-57% -$32.5K ﹤0.01% 5996
2021
Q4 		$91K Buy
+5,320
New +$129K ﹤0.01% 5693

Other funds holding TRDA

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
MC
Merck & Co Kenilworth, New Jersey $349M AUM 146.07% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
SG
StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wells Fargo's TRDA Position: Q1 2026 in Review

Wells Fargo reduced its Entrada Therapeutics (TRDA) stake by 66% in Q1 2026, selling an estimated $242K and leaving 11,011 shares worth $139K. The position accounts for ﹤0.01% of the portfolio, ranked #4925.

Wells Fargo first reported a position in TRDA in Q4 2021 and has held it in 18 quarters since. The position peaked at $331K in Q4 2025. 120 funds tracked by Wall St. Rank hold TRDA as of Q1 2026.

  • Wells Fargo held 11,011 shares of Entrada Therapeutics worth $139K as of Q1 2026.
  • Wells Fargo sold 21,152 Entrada Therapeutics shares in Q1 2026, an estimated $242K.
  • Entrada Therapeutics made up ﹤0.01% of Wells Fargo's portfolio in Q1 2026, its #4925 holding.
  • Wells Fargo first reported a position in Entrada Therapeutics in Q4 2021 and has held it in 18 quarters since.
  • Wells Fargo's Entrada Therapeutics position peaked at $331K in Q4 2025.
  • 120 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q1 2026.

Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.